Sotagliflozin

Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

Product Specifications

CAS Number

[1018899-04-1]

Product Name Alternative

LX-4211; LP-802034

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/LX-4211.html

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL

Smiles

ClC(C=CC([C@@H]1O[C@H](SC)[C@@H](O)[C@H](O)[C@H]1O)=C2)=C2CC3=CC=C(OCC)C=C3

Molecular Formula

C21H25ClO5S

Molecular Weight

424.94

Precautions

H302, H315, H319, H335

References & Citations

[1]Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92 (2) :158-69.|[2]Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1) -mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345 (2) :250-9.